Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: Yahoo! Finance
The consensus estimate for Q3 2024 revenue is $12.68 million, and the earnings are expected to come in at -$0.13 per share. The full year 2024's revenue is expected to be $58.01 million and the earnings are expected to be -$0.46 per share. More detailed estimate data can be found on the Forecast page Warning! GuruFocus has detected 6 Warning Signs with AQST. Over the past 90 days, revenue estimates for Aquestive Therapeutics Inc ( NASDAQ:AQST ) for the full year 2024 have increased from $49.79 million to $58.01 million. For 2025, the estimates have risen from $57.49 million to $57.76 million. Regarding earnings, estimates for 2024 have improved from -$0.49 per share to -$0.46 per share, while for 2025, estimates have declined from -$0.39 per share to -$0.46 per share. In the previous quarter of June 30, 2024, Aquestive Therapeutics Inc's ( NASDAQ:AQST ) actual revenue was $20.10 million, which beat analysts' revenue expectations of $12.38 million by 62.35%. Aquestive Therapeutic
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to FiveGlobeNewswire
- Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $17.00 price target on the stock.MarketBeat
AQST
Earnings
- 11/4/24 - Miss
AQST
Sec Filings
- 12/19/24 - Form 8-K
- 12/4/24 - Form 4
- 12/2/24 - Form 8-K
- AQST's page on the SEC website